CCMB’s turmeric, RNAi therapy tech to check cancer
Hyderabad: The researchers at Hyderabad-based Centre for Cellular and Molecular Biology (CCMB) have developed bio-drugs derived from turmeric that have shown regression or remission of cancerous tumours of colon and breast cancers.
The researchers have based their work on the field of RNA interference (RNAi), a gene silencing novel approach, in place of the traditional drugs used in chemotherapy, to develop therepautics meant to combat cancer.
The RNAi is a promising tool for targeted and focused therapy for chronic diseases like cancer. The lack of safe and effective delivery methods for RNAi molecules has been a key challenge against the use of RNAi-based therapy in biological systems, CCMB researchers said.
Dr. Lekha Dinesh Kumar and her group at CSIR-CCMB, in collaboration with the Polymer Science and Engineering Division at CSIR-NCL have developed nano-curcumin structures, which are derived from turmeric to encapsulate the RNAi (Ephb4 shRNA) and other molecules that aid in targeting specific tissues. The proposed bio-drug is non-toxic, bio-compatible with a higher uptake efficiency, and shows effective site-specific delivery with regression of tumors in two different mouse models of colon and breast cancer. This work has been published in the journal Nanoscale .
“The use of curcumin, a well-known nutraceutical with high anti-cancer and anti-inflammatory properties with RNAi showed tumor retardation with six months survival in aggressive models of colon and breast cancer,” said Dr. Kumar in a press release said.
In another study with the School of Nanosciences, Central University Gujarat and Centre for Advanced Materials and Industrial Chemistry, RMIT Australia, Dr Kumar’s team designed an eco-friendly and pH-responsive dietary fibre inulin-based nanodevice to target colon cancer.
This device suggests the possibility of substituting synthetic substances with natural compounds in bio-drug formulations for better bio-degradability, tissue accumulation, and lesser toxicity. The results from this work have been published in the journal Nanomedicine.
Dr. Kumar said, “In our studies, we have demonstrated that RNAi combined with appropriate targeting agents and encapsulations made of natural biomaterials have high translational capacity in mice models of cancer. This group of bio-drugs can revolutionise the field of cancer therapeutics in the future. It should be assessed in other cancer model systems to bring out the utility of these therapeutics in the clinical trials.”
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
